ONS Chemotherapy Immunotherapy Certificate Exam (NEW 2023/ 2024 Update) Questions and Verified Answers|100% Correct- Graded A

ONS Chemotherapy Immunotherapy Certificate Exam (NEW 2023/ 2024 Update) Questions and Verified Answers|100% Correct- Graded A QUESTION Lifetime dose of doxorubicin should not exceed: Answer: 550 mg/m^2 QUESTION What cardiac protectant medication can be administered prior to doxorubicin? Answer: Dexrazoxane QUESTION Significant side effects of doxorubicin are: Answer: Cardiotoxicity N/V Mucositis Diarrhea Severe myelosuppression Hepatic impairment Secondary cancers QUESTION Monitoring necessary with bleomycin: Answer: Pulmonary toxicity Hypersensitivity reactions (esp. in lymphoma patients) Cutaneous reactions Lifetime dose tracking (pulmonary toxicity) QUESTION Pulmonary fibrosis is possible when the lifetime dose of bleomycin exceeds: Answer: 400 units QUESTION What 6 patient characteristics make CINV more likely? Answer: 1. Younger than 50 years 2. Hx of low alcohol intake 3. Female gender 4. Hx of morning sickness during pregnancy 5. Prone to motion sickness 6. Previous chemotherapy QUESTION Types of CINV: Answer: Acute Delayed Breakthrough Anticipatory Refractory QUESTION Define acute CINV Answer: Occurring within 24 hours of chemotherapy QUESTION Define delayed CINV Answer: Occurring from 24 hours to 5 days after treatment QUESTION Define breakthrough CINV Answer: Occurring despite treatment QUESTION Define anticipatory CINV Answer: Triggered by taste, odor, memories, visions, or anxiety related to chemotherapy QUESTION Define refractory CINV Occurring during subsequent cycles when t